Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver crawled time : 12:00 save search
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 3.1%
H: 0.0%
C: -3.68%
hepatitis liver bemnifosbuvir treatment pharmaceuticals meeting virus
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
OMGA | $2.4 -0.83% -0.83% 400K
|
|
| O: 2.33%
H: 1.7%
C: -1.14%
liver control fibrosis preclinical therapeutics
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 1.98%
H: 0.49%
C: -2.43%
liver therapeutics
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: -3.49%
H: 6.58%
C: 6.25%
meeting liver presentation trial
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
ALGS | $0.735 -7.33% -7.9% 140K
|
Health Technology
|
| O: 0.16%
H: 3.13%
C: 0.75%
alg-0001 meeting drug liver therapeutics
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 2.12%
H: 1.45%
C: -1.66%
meeting liver presentation
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-19 (Crawled : 12:00) - globenewswire.com
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -0.3%
H: 3.26%
C: 2.74%
meeting liver presentation bexotegrast therapeutics
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Published: 2023-10-18 (Crawled : 12:00) - globenewswire.com
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: -3.73%
meeting liver presentation response
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Published: 2023-10-13 (Crawled : 12:00) - globenewswire.com
THTX | $1.29 -12.78% 8.1K
|
Health Technology
|
| O: -6.63%
H: 11.24%
C: 4.14%
liver hiv week
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
ABUS | $2.725 -0.18% -0.18% 930K
|
Health Technology
|
| O: 5.41%
H: 0.51%
C: -4.1%
meeting liver presentation
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
ASMB | $13.64 2.33% 2.27% 11K
|
Health Technology
|
| O: -4.16%
H: 11.6%
C: 5.71%
meeting liver
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -0.9%
H: 2.27%
C: 0.68%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -1.16%
H: 1.43%
C: 0.43%
meeting hepatitis liver presentation
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
Published: 2023-10-05 (Crawled : 12:00) - biospace.com/
BTTX | $0.009 -65.02% 180K
|
|
| O: 1.13%
H: 5.96%
C: -7.68%
liver disease publication therapeutics results study
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis
Published: 2023-10-03 (Crawled : 12:00) - globenewswire.com
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: -2.08%
H: 3.72%
C: 3.19%
cirrhosis liver positive meeting hypertension therapeutics study
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 0.0%
H: 3.24%
C: -1.63%
cirrhosis liver update program therapeutics
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: 76.15%
H: 1.79%
C: 1.74%
rare liver pharmaceuticals global acquire
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
Published: 2023-08-29 (Crawled : 12:00) - globenewswire.com
OCEA | $1.76 -6.13% -6.53% 200K
|
|
| O: 7.33%
H: 0.83%
C: -10.14%
patent liver disease
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.